Hypertension as a part of metabolic syndrome

Česká verzia

Authors: H. Němcová
Authors place of work: II. interní klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2005; 51(1): 66-70
Category: Reviews

Summary

Metabolic syndrome is a set of symptoms and diseases the integrating factor of whose is decreased tissue insulin sensitivity. Its consequences are still more important and they are prognostically serious since they relate to the diseases with mass occurence, as obesity, hypertension, diabetes, hyperlipoproteinemy. Increased insulin level as a consequence of insulinresistance leads to the weight, blood pressure and aterogenous lipids increase, significantly accelerating aterosclerosis, which is the main death cause. Therefore early detection of metabolic syndrome before the development of organ complications is necessary as well as introduction of the preventive and therapeutical measures that would decrease the cardiovascular risk as much as possible. In hypertension it means its early detection and complex effective treatment to reach both optimal blood pressure values at the concrete individual and the influence of present metabolic abnormalities. Lifestyle modification is necessary because the environmental factors significantly influence the extent to which the genetic predisposition will be exerted at last.

Key words:
metabolic syndrome – insulin resistance – hypertension – diabetes mellitus – prevention – lifestyle modification – – pharmacotherapy

Zdroje

1. Dvořák I, Blaha M et al. Odhad rizika hypertenze u osob s normálním krevním tlakem s rodinnou zátěží. Vnitř Lék 1984; 30: 324–330.

2. Kisters K, Tokmak F et al. Role of the Na+/Mg2+ exchanger in hypertension. Amer J Hypertens 2003; 1(16): 95–96.

3. Kjeldsen SE, Rosstrup M et al. The sympatic nervous system may modulate the metabolic cardiovascular syndrom in essential hypertension. J Cardiovasc Pharmacol 1992; 20 (Suppl 8).

4. Landsberg L. Insulin mediated sympathetic stimulation: role in the pathogenesis of obesity–related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 2001; 19: 523–528.

5. Modan M, Halkin H et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809–817.

6. Němcová H, Dvořák I et al. Změny krevního tlaku u lehkých forem hypertenze po dlouhodobém tělesném tréninku. Vnitř Lék 1989; 35(1): 30–35.

7. Perušičová J, Anděl M, Hořejší J. Diabetes mellitus a poruchy metabolizmu lipidů. Praha: Galén 2000.

8. Reaven G. Insulin resistance, Hypertension, and Coronary heart Disease. J Clin Hypertension 2003; 4: 269–274.

9. Rosolová H. Arteriální hypertenze a diabetes mellitus. In: Perušičová J (ed). Trendy soudobé diabetologie. Praha: Galén 1999; 3. vol.

10. Svačina Š, Owen K. Syndrom inzulínové rezistence. Praha: Triton 2003.

11. Tsuda K. Hyperinsulinemia, intracelullar calcium, and membrane function in essential hypertension. Amer J Hypert 2003; 16(1): 19–21.

12. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr 1956; 4: 20–34.